A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of
an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or
V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have
received any local brain therapy, and subjects in Cohort B will have received prior local
therapy for brain metastases. Subjects will continue on treatment until disease progression,
death, or unacceptable adverse event.